Oligodeoxynucleotide and its use to induce an immune response

Details Oligodeoxynucleotide and its use to induce an immune response Oligodeoxynucleotide and its use to induce an immune response

2006-11-09

2011-10-04

Minnifield, Nita M (Department: 1645)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S184100, C424S278100, C424S450000

Reexamination Certificate

active

08030285

ABSTRACT:
The present invention provides a substantially pure or isolated oligodeoxynucleotide of at least about 10 nucleotides comprising a sequence represented by either the formula:in-line-formulae description="In-line Formulae" end="lead"?5′N1N2N3T-CpG-WN4N5N63′in-line-formulae description="In-line Formulae" end="tail"?wherein the central CpG motif is unmethylated, W is A or T, and N1, N2, N3, N4, N5, and N6are any nucleotides, or the formula:in-line-formulae description="In-line Formulae" end="lead"?5′RY-CpG-RY3′in-line-formulae description="In-line Formulae" end="tail"?wherein the central CpG motif is unmethylated, R is. A or G, and Y is C or T, as well as an oligodeoxynucleotide delivery complex and a pharmacological composition comprising the present inventive oligodeoxynucleotide, and a method of inducing an immune response by administering the present inventive oligodeoxynucleotide to a host.

REFERENCES:
patent: 6194388 (2001-02-01), Krieg et al.
patent: 6207646 (2001-03-01), Krieg et al.
patent: 6214806 (2001-04-01), Krieg et al.
patent: 6218371 (2001-04-01), Krieg et al.
patent: 6239116 (2001-05-01), Krieg et al.
patent: 6339068 (2002-01-01), Krieg et al.
patent: 6406705 (2002-06-01), Davis et al.
patent: 6423539 (2002-07-01), Fong et al.
patent: 6428788 (2002-08-01), Debinski et al.
patent: 6429199 (2002-08-01), Krieg et al.
patent: 6498148 (2002-12-01), Raz
patent: 6514948 (2003-02-01), Raz et al.
patent: 6534062 (2003-03-01), Raz et al.
patent: 6552006 (2003-04-01), Raz et al.
patent: 6562798 (2003-05-01), Schwartz
patent: 6589940 (2003-07-01), Raz et al.
patent: 6610661 (2003-08-01), Carson et al.
patent: 6613751 (2003-09-01), Raz et al.
patent: 6653292 (2003-11-01), Krieg et al.
patent: 6977245 (2005-12-01), Klinman et al.
patent: 7354909 (2008-04-01), Klinman et al.
patent: 7517861 (2009-04-01), Krieg et al.
patent: 7521063 (2009-04-01), Klinman et al.
patent: 7534772 (2009-05-01), Weiner et al.
patent: 7585847 (2009-09-01), Bratzler et al.
patent: 7615227 (2009-11-01), Klinman et al.
patent: 7666674 (2010-02-01), Klinman et al.
patent: 7674777 (2010-03-01), Krieg et al.
patent: 7699801 (2010-04-01), Haynes et al.
patent: 7713529 (2010-05-01), Krieg et al.
patent: 7723022 (2010-05-01), Krieg et al.
patent: 7723500 (2010-05-01), Krieg et al.
patent: 7758876 (2010-07-01), Klinman et al.
patent: 7879810 (2011-02-01), Krieg et al.
patent: 7892569 (2011-02-01), Klinman et al.
patent: 7919477 (2011-04-01), Klinman et al.
patent: 7935351 (2011-05-01), Klinman et al.
patent: 2001/0034330 (2001-10-01), Kensil
patent: 2001/0036462 (2001-11-01), Fong et al.
patent: 2001/0044416 (2001-11-01), McCluskie et al.
patent: 2001/0046967 (2001-11-01), Van Nest
patent: 2002/0006403 (2002-01-01), Yu et al.
patent: 2002/0028784 (2002-03-01), Van Nest
patent: 2002/0042383 (2002-04-01), Yew et al.
patent: 2002/0042387 (2002-04-01), Raz et al.
patent: 2002/0055477 (2002-05-01), Van Nest et al.
patent: 2002/0064515 (2002-05-01), Krieg et al.
patent: 2002/0065236 (2002-05-01), Yew et al.
patent: 2002/0086295 (2002-07-01), Raz et al.
patent: 2002/0086839 (2002-07-01), Raz et al.
patent: 2002/0090724 (2002-07-01), Taylor et al.
patent: 2002/0091095 (2002-07-01), Phillips et al.
patent: 2002/0091097 (2002-07-01), Bratzler et al.
patent: 2005/0209184 (2005-09-01), Klinman et al.
patent: 2007/0202575 (2007-08-01), Klinman et al.
patent: 2011/0033421 (2011-02-01), Hartmann et al.
patent: 2011/0038896 (2011-02-01), Van Nest et al.
patent: 1 198 249 (2002-04-01), None
patent: WO 92/18522 (1992-10-01), None
patent: WO 94/19945 (1994-09-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO 97/28259 (1997-08-01), None
patent: WO 98/18810 (1998-05-01), None
patent: WO 98/37919 (1998-09-01), None
patent: WO 99/11275 (1999-03-01), None
patent: WO 00/06588 (2000-02-01), None
patent: WO 00/20039 (2000-04-01), None
patent: WO 00/21556 (2000-04-01), None
patent: WO 00/61151 (2000-10-01), None
patent: WO 00/62787 (2000-10-01), None
patent: WO 00/67023 (2000-11-01), None
patent: WO 01/00232 (2001-01-01), None
patent: WO 01/02007 (2001-01-01), None
patent: WO 01/12223 (2001-02-01), None
patent: WO 01/22990 (2001-04-01), None
patent: WO 01/51500 (2001-07-01), None
patent: WO 01/55341 (2001-08-01), None
patent: WO 01/68077 (2001-09-01), None
patent: WO 01/68103 (2001-09-01), None
patent: WO 01/68116 (2001-09-01), None
patent: WO 01/68117 (2001-09-01), None
U.S. Patent No. 6,008,200, issued Dec. 28, 1999, Withdrawn.
Anfossi, et al., “An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines”. Proc. Natl, Acad. Sci. USA 86:3379-3383 (1989).
Bauer, et al., “Bacterial CpG-Dna Triggers Activation and Maturation of Human CD11c−, CD123+ Dendritic Cells”. J. Immunol. 166:5000-5007 (2001).
Benimetskaya, et al., “Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (NF-kBp65) ‘antisense’ oligodeoxynucleotide”. Nucleic Acids Research 25(13):2648-2656 (1997).
Boggs, et al., “Characterization and modulation of immune stimulation by modified oligonucleotides”. Antisense Nucl. Acid Drug Dev. 7(5):461-471 (1997).
Branda, et al., “Amplification of antibody production by phosphorothioate oligodeoxynucleotides”. J. Lab Clin. Med. 128(3):329-338 (1996).
Chu, et al., “CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity”. J. Exp. Med. 186(10):1623-1631 (1997).
Deml, et al., “Immunostimulatory CpG motifs trigger a T Helper-1 immune response to Human Immunodeficiency Virus Type-1 (HIV-1) gp160 envelope protein”. Clin. Chem. Lab. Med. 37(3):199-204 (1999).
Gao, et al., “Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and Rnase H: Implications for antisense technology”. Mol. Pharmacol. 41:223-229 (1992).
Gursel, et al., “Differential and Competitive Activation of Human Immune Cells by Distinct Classes of CpG Oligodeoxynucleotide”. J. Leuko. Biol. 71:813-820 (2002).
Halpern, et al., “Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha”. Cell Immunol. 167(1):72-78 (1996).
Ishibashi, et al., “Sp1 Decoy Transfected to Carcinoma Cells Suppresses the Expression of Vascular Endothelial Growth Factor, Transforming Growth Factor β, and Tissue Factor and Also Cell Growth and Invasion Activities”. Cancer Research 60:6531-6536 (2000).
Iversen, et al., “Pharmacokinetics of an antisense phosphorothioate oigodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single inections and continuous infusion”. Antisense Res. Dev. 4:43-52 (1994).
Jilek, et al., “Antigen-Independent Suppression of the Allergic Immune Response to Bee Venom Phospholipase A2 by DNA Vaccination in CBA/J Mice”. J. Immunol. 166:3612-3621 (2001).
Kadowaki, et al., “Distinct CpG DNA and Polyinosinic-Polycytidylic Acid Double Stranded RNA, Respectively, Stimulate CD11c− Type 2 Dendritic Cell Precursoes and CD11c+ Dendritic cells to Produce Type I IFN”. J. Immunol. 166:2291-2295 (2001).
Klinman, et al., “Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety”. Springer Semin. Immunopathol. 22:173-183 (2000).
Krieg, et al., “CpG motifs in bacterial DNA and their immune effect”. Annu. Rev. Immunol. 20:709-760 (2002).
Krieg, et al., “Brief Communication: Oligodeoxynucleotide Modifications Determine the Magnitude of B-Cell Stimulation by CpG Motifs”. Antisense & Nucleic Acid Drug Development 6:133-139 (1996).
Krieg, et al., “Leukocyte stimulation by oligodeoxynucleotides”. Applied Antisense Oligonucleotide Tech. (BOOK):431-448 (1998).
Krieg, et al., “CpG DNA: A pathogenic factor in systemic lupus erythematosus?”. J. Clin. Immunol. 15(6):284-292 (19

Affiliated with

Also associated with

Rating

Oligodeoxynucleotide and its use to induce an immune response does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oligodeoxynucleotide and its use to induce an immune response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligodeoxynucleotide and its use to induce an immune response will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4300336